Cyclacel Pharmaceuticals Inc. ( CYCC ) experienced a 34.56% surge in its stock value during after-hours on Monday.

Check out the current price of CYCC stock here. 

What Happened: The stock value of the clinical-stage biopharmaceutical company soared to $13.20 in the after-hours trading session, marking a 34.56% increase. This surge followed the company’s announcement of promising preclinical data for the treatment of biliary tract cancer.

See Also: Jim Cramer Says Palantir’s ‘Next Stop Is $200’ After Q2 Earnings Blowout: Dan Ives Calls It ‘The Messi of AI’

The data, which was highlighted by the company, suggests that BTC is sensitive to plogosertib, a PLK1 inhibitor. The study, titled “Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker,” was conducted by independent investigators and published in the journal Cancer Research.

Why It Matters: The study found that several BTC cancer cell lines were sensitive to plogosertib, both as monotherapy and in combinations. The study also suggested that BUBR1, a critical mitotic checkpoint protein, could be used as a biomarker to assess plogosertib's effectiveness. The findings indicate that targeting PLK1 could be an effective strategy for BTC treatment, especially with BUBR1 expression as a potential biomarker to inform optimal combination therapies.

This promising preclinical data has evidently sparked investor interest, leading to a significant surge in the company’s stock value. 

Price in Action: According to Benzinga Pro data, Cyclacel Pharmaceuticals ( CYCC ) closed at $9.81 on Monday, up 0.93% from the previous day, and was trading at $13.20 in the late trading session, up 34.56%. It has an average trading volume of 3.63 million shares.

Benzinga’s Edge Stock Rankings indicate a negative price trend across all time frames. Additional performance details are available here.

Read Next: Shiba Inu Could Surge 3,000% and Overtake Dogecoin by 2026, Say Analysts

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.